Setmelanotide for treating obesity caused by LEPR or POMC deficiency [ID3764]
In development [GID-HST10034] Expected publication date: 20 July 2022
Search results
477 results
-
-
Eladocagene exuparvovec for treating aromatic L-amino acid decarboxylase deficiency [ID3791]
In development [GID-HST10052] Expected publication date: 29 March 2023
-
Sebelipase alfa for treating Wolman disease [ID3995]
In development [GID-HST10047] Expected publication date: TBC
-
Velmanase alfa for treating alpha-mannosidosis [ID800]
In development [GID-HST10010] Expected publication date: TBC
-
Human alpha1-proteinase inhibitor for treating emphysema ID856
In development [GID-HST10017] Expected publication date: TBC
-
Afamelanotide for treating erythropoietic protoporphyria [ID927]
In development [GID-HST10009] Expected publication date: TBC
-
Palovarotene for treating flare ups of heterotopic ossification associated with fibrodysplasia ossificans progressiva [ID2721]
In development [GID-HST10033] Expected publication date: TBC
-
Ataluren for treating Duchenne muscular dystrophy with a nonsense mutation in the dystrophin gene (review of HST3) ID1642
In development [GID-HST10044] Expected publication date: 25 January 2023
-
Lysosomal acid lipase deficiency - sebelipase alfa [ID737]
In development [GID-LYSOSOMALACIDLIPASEDEFICIENCYSEBELIPASEALFAID737] Expected publication date: TBC
-
Onasemnogene abeparvovec for treating spinal muscular atrophy (review of HST15) [ID4051]
In development [GID-HST10053] Expected publication date: TBC
-
Zanubrutinib for treating Waldenström's macroglobulinaemia [ID1427]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 26 May 2022.
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 6 June 2022.
-
Lumasiran for treating primary hyperoxaluria type 1 [ID3765]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 13 June 2022.
-
Tucatinib with trastuzumab and capecitabine for treating HER2-positive unresectable locally advanced or metastatic breast cancer after 2 or more anti-HER2 therapies [ID3828]: appraisal consultation
We are listening to your views on this Technology appraisal guidance. Comments close 16 November 2021.
-
Avacopan for treating severe active granulomatosis with polyangiitis or microscopic polyangiitis [ID1581]: draft guidance
We are listening to your views on this Technology appraisal guidance. Comments close 17 June 2022.
-
Imlifidase for preventing kidney transplant rejection in people with chronic kidney disease [ID1672]
In development [GID-TA10552] Expected publication date: 13 July 2022
-
Burosumab for treating FGF23-related hypophosphataemia in tumour-induced osteomalacia [ID3924 ]
In development [GID-TA10822] Expected publication date: TBC
-
Tebentafusp for treating advanced (unresectable or metastatic) uveal melanoma [ID1441]
In development [GID-TA10428] Expected publication date: 20 July 2022
-
Abemaciclib for adjuvant treatment of hormone receptor-positive, HER2-negative, node-positive early breast cancer [ID3857]
In development [GID-TA10749] Expected publication date: TBC
-
Sacituzumab govitecan for treating unresectable locally advanced or metastatic triple-negative breast cancer after 2 or more therapies [ID3942]
In development [GID-TA10829] Expected publication date: 17 August 2022
-
Tisagenlecleucel for treating follicular lymphoma after 2 or more therapies [ID3950]
In development [GID-TA10849] Expected publication date: 19 July 2023
-
Relugolix–estradiol–norethisterone acetate for treating moderate to severe symptoms of uterine fibroids [ID3842]
In development [GID-TA10734] Expected publication date: 22 June 2022
-
Pembrolizumab with lenvatinib for previously treated advanced, metastatic or recurrent endometrial cancer [ID3811]
In development [GID-TA10692] Expected publication date: 04 January 2023
-
Palbociclib with fulvestrant for treating hormone receptor-positive, HER2-negative, advanced breast cancer (Review of TA619) [ID3779]
In development [GID-TA10901] Expected publication date: 23 November 2022
-
Lu vipivotide tetraxetan for treating PSMA-positive hormone-relapsed metastatic prostate cancer after 2 or more therapies [ID3840]
In development [GID-TA10730] Expected publication date: 23 November 2022
-
Pembrolizumab in combination with chemotherapy for neoadjuvant treatment of triple negative breast cancer [ID1500]
In development [GID-TA10399] Expected publication date: 23 November 2022
-
Eflornithine for maintenance treatment of high-risk neuroblastoma after 1 therapy in people up to 21 years [ID4060]
In development [GID-TA10990] Expected publication date: TBC
-
Olaparib with abiraterone for untreated hormone-relapsed metastatic prostate cancer [ID3920 ]
In development [GID-TA10802] Expected publication date: TBC
-
Pembrolizumab for adjuvant treatment of resected non-small-cell lung cancer [ID3907 ]
In development [GID-TA10784] Expected publication date: TBC
-
Nivolumab with chemotherapy for neoadjuvant treatment of early non-small-cell lung cancer [ID3757]
In development [GID-TA10632] Expected publication date: TBC
-
Vadadustat for treating anaemia in people with chronic kidney disease [ID3821]
In development [GID-TA10877] Expected publication date: TBC
-
Rimegepant for treating or preventing migraine [ID1539]
In development [GID-TA10839] Expected publication date: 01 March 2023
-
Finerenone for treating chronic kidney disease in people with type 2 diabetes [ID3773]
In development [GID-TA10820] Expected publication date: 14 September 2022
-
Filgotinib for treating moderately to severely active ulcerative colitis [ID3736]
In development [GID-TA10600] Expected publication date: 08 June 2022
-
Mosunetuzumab for treating relapsed or refractory follicular lymphoma [ID3931]
In development [GID-TA10816] Expected publication date: 25 January 2023
-
Oleogel-S10 for treating skin wounds associated with epidermolysis bullosa ID1505
In development [GID-TA10654] Expected publication date: TBC
-
Darolutamide with androgen deprivation therapy and docetaxel for treating hormone-sensitive metastatic prostate cancer [ID3971]
In development [GID-TA10860] Expected publication date: TBC
-
Diroximel fumarate for treating relapsing-remitting multiple sclerosis [ID1673]
In development [GID-TA10714] Expected publication date: 08 June 2022
-
Ibrutinib for treating Waldenstrom's macroglobulinaemia (CDF Review of TA491) [ID3778]
In development [GID-TA10827] Expected publication date: 08 June 2022
-
Targeted-release budesonide for treating IgA nephropathy ID1434
In development [GID-TA11028] Expected publication date: TBC
-
Natalizumab for treating highly active relapsing-remitting multiple sclerosis [ID4020]
In development [GID-TA11056] Expected publication date: TBC
-
Beremagene geperpavec for treating dystrophic epidermolysis bullosa in children, young people and adults [ID3959]
In development [GID-TA10868] Expected publication date: TBC
-
Pembrolizumab with platinum-based chemotherapy and radiation for treating unresectable locally advanced squamous cell carcinoma of the head and neck [ID1667]
In development [GID-TA10567] Expected publication date: 18 October 2023
-
Venetoclax for treating chronic lymphocytic leukaemia (CDF review of TA487) [ID3886]
In development [GID-TA10890] Expected publication date: 15 June 2022
-
Pembrolizumab for adjuvant treatment of resected stage 2 melanoma with high risk of recurrence [ID3908 ]
In development [GID-TA10786] Expected publication date: TBC
-
Nivolumab in combination for untreated advanced unresectable recurrent or metastatic oesophageal squamous cell carcinoma [ID2712]
In development [GID-TA10572] Expected publication date: 23 November 2022
-
Voclosporin with immunosuppressives for treating lupus nephritis [ID3962]
In development [GID-TA10878] Expected publication date: 25 January 2023
-
Autologous auto-CD19-transduced CD3+ cells for treating relapsed or refractory B-precursor acute lymphoblastic leukaemia in adults ID1494
In development [GID-TA10424] Expected publication date: 14 December 2022
-
Capmatinib for treating advanced non-small-cell lung cancer with MET exon 14 skipping [ID1387]
In development [GID-TA10846] Expected publication date: TBC
-
Nivolumab-relatlimab for untreated advanced or metastatic melanoma [ID1688]
In development [GID-TA10581] Expected publication date: TBC